Drug Profile
Ceruloplasmin
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Aventis; University of Montreal
- Class Acute-phase proteins; Anti-inflammatories; Anti-ischaemics; Antiarrhythmics; Antihyperlipidaemics; Metalloproteins
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 10 Jan 2000 No-Development-Reported for Arrhythmias in Canada (Unknown route)
- 20 Feb 1997 Preclinical development for Arrhythmias in Canada (Unknown route)